why choose us

First received: September 05, 2023

Clinical Trial: A Study to Assess Change in Disease Activity, Adverse Events, and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion of Budigalimab and/or ABBV-382

Study Status: Completed

Recruit Status: RECRUITING

Condition: Human Immuno-deficiency Virus (HIV) Disease

Study Type: INTERVENTIONAL


Official Title: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-controlled Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacokinetics of Budigalimab and/or ABBV-382 in People Living With HI

Brief Summary: Human immuno-deficiency virus (HIV) is the virus that causes Acquired Immuno-Deficiency Syndrome (AIDS).HIV disease is considered to be a chronic disease requiring lifelong therapy.The purpose of this study is to assess change in disease activity, adverse events, tolerability, and how the drug moves through the body.Budigalimab and ABBV-382 are investigational drugs being developed for the treatment of HIV disease.Participants are placed in 1 of 5 groups, called treatment arms.Each group receives a different…

Read more